

## Current Status

### 9<sup>th</sup> Merger

Thank you to everyone who has been working hard to complete the 9<sup>th</sup> Merger of the D:A:D database and the related queries, completing event forms and facilitating the monitoring before the data lock. The success of this study is a consequence of the high quality of the data, and hence the awareness and meticulous work of numerous study personnel in the study. Thank you!

## New Endpoints in D:A:D Study

The Oversight Committee and the D:A:D Steering Committee have been working together to outline further areas where the D:A:D study could provide insight into the effects of ART.

The proposal approved by the D:A:D Steering Committee and each of the cohorts internal governing bodies, is to include 3 new additional endpoints. They include: Non-AIDS defining cancers; End-stage renal disease; and Chronic liver disease. The study will continue to collect data on MI, Stroke, Invasive cardiovascular procedures, diabetes, and death as we have always done.

The data collection for these new endpoints has been initiated. Additionally, data collection for these events retrospectively will be initiated on a cohort specific basis.

Currently, over 60% of deaths among HIV-infected persons receiving cART are from causes other than AIDS. An increasing proportion of HIV patients are diagnosed with a non-AIDS defining cancer

End-stage kidney and liver diseases are more rare and it is therefore the DAD study—due to its large size—that is in the unique position to be able to capture emerging trends with these diseases.

The SMART and D:A:D study groups will be presenting analyses from the SMART study in relation to Abacavir at the late breaker session on **Thursday the 7th August, during the XVII International AIDS Conference in México City, México.**

## Recent Publications

**Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction.** Data Collection on Adverse Events of Anti-HIV Drugs Study Group, CA Sabin, A d'Arminio Monforte, N Friis-Møller, R Weber, WM El-Sadr, P Reiss, O Kirk, P Mercie, MG Law, S De Wit, C Pradier, AN Phillips, JD Lundgren. Clin Infect Dis. 2008 Apr 1;46(7):1101-10 [Abstract](#)

**Incidence and risk factors for new onset diabetes mellitus in HIV infected patients: the D:A:D study.** De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanova C, El-Sadr W, Monforte A, Fontas E, Law MG, Friis-Møller N, Phillips A; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care. 2008 Jun;31(6):1224-9. Epub 2008 Feb 11. [Article](#)

**Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.** Writing group: CA Sabin, SW Worm, R Weber, P Reiss, W E l Sadr, F Dabis, S De Wit, M Law, A D'Arminio Monforte, N Friis-Møller, O Kirk, C Pradier, I Weller, AN Phillips, JD Lundgren. [Lancet](#). 2008 Apr 26;371(9622):1417-26. E pub 2008 Apr 2. *In connection with this publication in The Lancet, the D:A:D steering committee released a position statement which can be accessed here: [position statement](#)*

## Presentations

15th Conference on Retroviruses and Opportunistic Infections, Boston, February 2008, POSTERS

**Hepatitis Virus Co-infections and Risk of Diabetes Mellitus (DM) and Myocardial Infarction (MI) in HIV-infected Persons: The D:A:D Study.** R Weber, C Sabin, P Reiss, S De Wit, S Worm, M Law, F Dabis, A d'Arminio Monforte, E Fontas, J Lundgren [Poster No. 1082 82 KB](#)

**Do Thymidine Analogues, Abacavir, Didanosine and Lamivudine Contribute to the Risk of Myocardial Infarction (MI)?** Recent Use of Abacavir and Didanosine, but not of Thymidine Analogues, Is Associated with Risk of Myocardial Infarction. Writing group: CA Sabin, SW Worm, R Weber, P Reiss, W E l Sadr, R Thiebaut, S De Wit, M Law, A D'Arminio Monforte, N Friis-Møller, O Kirk, C Pradier, S Collins, I Weller, AN Phillips, JD Lundgren on behalf of the D:A:D study group. [Poster No. 957c 121 KB](#)